Larimar Therapeutics (LRMR) Invested Capital (2014 - 2020)

Larimar Therapeutics (LRMR) has reported Invested Capital for 7 consecutive years, with $16.3 million the latest figure, recorded in Q1 2020.

• For the quarter ending Q1 2020, Invested Capital fell 26.1% year-over-year to $16.3 million; the trailing twelve-month figure through Mar 2020 stood at $16.3 million (down 26.1% YoY), and the FY2019 full-year result was $15.0 million, down 36.13% from the prior year.
• Invested Capital rose to $16.3 million in Q1 2020 per LRMR's latest filing, from $15.0 million in the prior quarter.
• Across five years, Invested Capital topped out at $160.1 million in Q1 2016 and bottomed at $15.0 million in Q4 2019.
• Historically, Invested Capital has averaged $80.9 million across 5 years, with a median of $90.5 million in 2017.
• The sharpest annual moves came in 2018 and 2019: Invested Capital soared 41.52% in 2018, then plunged 84.9% in 2019.
• Over 5 years, Invested Capital stood at $125.3 million in 2016, then retreated by 21.62% to $98.2 million in 2017, then slumped by 76.02% to $23.6 million in 2018, then slumped by 36.13% to $15.0 million in 2019, then increased by 8.2% to $16.3 million in 2020.
• According to Business Quant data, Invested Capital over the past three periods registered $16.3 million, $15.0 million, and $19.3 million for Q1 2020, Q4 2019, and Q3 2019 respectively.